Get the Stockscreener App
62.55
5.04%
3.00
Pre-market:
65.88
3.33
+5.32%
Disc Medicine Inc stock is traded at $62.55, with a volume of 259.91K.
It is up +5.04% in the last 24 hours and up +23.71% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
See More
Previous Close:
$59.55
Open:
$59.1
24h Volume:
259.91K
Relative Volume:
0.93
Market Cap:
$1.86B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-15.80
EPS:
-3.9598
Net Cash Flow:
$-74.38M
1W Performance:
-0.81%
1M Performance:
+23.71%
6M Performance:
+93.23%
1Y Performance:
+22.38%
1-Day Range:
$59.10
$62.69
1-Week Range:
$56.28
$63.83
52-Week Range:
$25.60
$77.60
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| IRON | 62.55 | 1.86B | 0 | -91.00M | -74.38M | -3.9598 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine secures $200m financing to support trials - MSN
Contrasting Pharming Group (OTCMKTS:PHGUF) and Disc Medicine (NASDAQ:IRON) - Defense World
Disc Medicine chief medical officer sells $546,152 in stock - Investing.com
Disc Medicine chief medical officer sells $546,152 in stock By Investing.com - Investing.com UK
Disc Medicine Announces New Equity Sales Agreement - TipRanks
FY2024 EPS Estimates for Disc Medicine Raised by Analyst - MarketBeat
Wedbush Forecasts Disc Medicine's Q4 Earnings (NASDAQ:IRON) - MarketBeat
Disc Medicine FY2024 EPS Estimate Raised by Leerink Partnrs - MarketBeat
Lifesci Capital Predicts Stronger Earnings for Disc Medicine - MarketBeat
Disc Medicine FY2024 EPS Forecast Boosted by HC Wainwright - MarketBeat
Paradigm Biocapital Advisors LP Adjusts Stake in Disc Medicine I - GuruFocus.com
Analysts Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $85.80 - MarketBeat
FY2028 Earnings Forecast for Disc Medicine Issued By Wedbush - MarketBeat
Disc Medicine Reports Q3 2024 Results and Strategic Progress - TipRanks
Disc Medicine (NASDAQ:IRON) Announces Quarterly Earnings Results - MarketBeat
Disc Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Disc Medicine stock gets price target bump from H.C. Wainwright, Buy rating intact - Investing.com UK
Disc Medicine (IRON) to Present at Major Healthcare Investor Conferences | IRON Stock News - StockTitan
Learn to Evaluate (IRON) using the Charts - Stock Traders Daily
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Disc Medicine Secures $200M Financing, Reports FDA Fast-Track Potential for Key Drug | IRON Stock News - StockTitan
Disc Medicine Inc. (IRON) Quarterly 10-Q Report - Quartzy
Disc Medicine secures $200M in debt financing from Hercules Capital - MSN
Scotiabank Boosts Disc Medicine (NASDAQ:IRON) Price Target to $70.00 - Defense World
Wellington Management Group LLP Increases Stake in Disc Medicine Inc - GuruFocus.com
Disc Medicine Leaps on Investment - Baystreet.ca
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital - citybiz
Disc Medicine Secures $200 Million in Financing - citybiz
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. - The Manila Times
Disc Medicine Secures Massive $200M Financing Deal to Advance Clinical Pipeline | IRON Stock News - StockTitan
FY2024 Earnings Forecast for Disc Medicine Issued By Wedbush - Defense World
Leerink Partnrs Forecasts Weaker Earnings for Disc Medicine - MarketBeat
Disc Medicine (NASDAQ:IRON) Stock Rating Upgraded by Raymond James - Defense World
FY2024 Earnings Estimate for Disc Medicine Issued By Wedbush - MarketBeat
Disc Medicine Announces Multiple Presentations Across - GlobeNewswire
Disc Medicine (IRON) Rally Strengthens With After-Hour Gains On Positive Clinical Milestone - Stocks Telegraph
Disc medicine director sells $427,525 in stock By Investing.com - Investing.com South Africa
Disc medicine director sells $427,525 in stock - Investing.com
Disc Medicine (NASDAQ:IRON) Stock Price Up 7%Here's Why - MarketBeat
HC Wainwright Reaffirms Buy Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Scotiabank upgrades Disc Medicine shares target on trial update By Investing.com - Investing.com UK
Disc Medicine to Present Complete DISC-0974 Trial Data, Portfolio Updates at ASH 2024 | IRON Stock News - StockTitan
Disc Medicine stock target upgraded on bitopertin prospects By Investing.com - Investing.com Canada
Disc Medicine (NASDAQ:IRON) Upgraded at Morgan Stanley - MarketBeat
FDA aligns with Disc Medicine on EPP treatment study - Investing.com India
Wedbush Reaffirms Outperform Rating for Disc Medicine (NASDAQ:IRON) - MarketBeat
Disc over the moon as FDA urges Apollo bid with bitopertin in EPP - BioWorld Online
FDA aligns with Disc Medicine on EPP treatment study By Investing.com - Investing.com Canada
Disc Medicine stock rallies 26% on FDA update for bitopertin (update) - Seeking Alpha
Disc Medicine Shares Rise After Positive Feedback From FDA - Marketscreener.com
Disc Medicine (NASDAQ:IRON) Shares Gap UpTime to Buy? - MarketBeat
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Disc Medicine Inc Stock (IRON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Savage William Jacob | Chief Medical Officer |
Nov 15 '24 |
Sale |
59.64 |
9,158 |
546,153 |
40,405 |
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):